JP Morgan Maintains Overweight on Travere Therapeutics, Lowers Price Target to $41

Benzinga Newsdesk www.benzinga.com Negative 86.0%

Neg 86% Neu 0% Pos 0%

JP Morgan analyst Anupam Rama maintains Travere Therapeutics (NASDAQ:TVTX) with a Overweight and lowers the price target from $44 to $41.